Share Price:

APNASPENAspen Pharmacare Hldgs13411-89 (-0.66%)

Aspen is in a closed period from 1st January 2026 until the publication of the interim results on the JSE SENS platform on the 3rd March 2026.

Aspen debuts in the FTSE4Good Index Series

The annual FTSE Russell Environmental, Social and Governance (ESG) Ratings have been published and Aspen has been included as a constituent member in the global FTSE4Good Index Series for the first time. Jeanette Englund Aspen Group Risk Sustainability Manager said, “We are delighted to be included in the global FTSE4Good Index Series for the first… Continue reading Aspen debuts in the FTSE4Good Index Series

Aspen donates electronic devices valued at R2.4 million to assist UP medical students

An Aspen Pharmacare initiative Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (Aspen), a global multinational specialty pharmaceutical company headquartered in South Africa, has donated 600 internet-enabled electronic devices valued at R2.4 million to support students from the Faculty of Health Sciences at the University of Pretoria (UP). Stavros Nicolaou, Aspen Pharmacare Senior Executive: Strategic Trade said, “Aspen… Continue reading Aspen donates electronic devices valued at R2.4 million to assist UP medical students

AGI: Covid-19 support in Mauritius

Aspen donates anaesthetic medicines to patients in critical condition An Aspen Global Incorporated Initiative Ministry of Health, Emmanuel Anquetil Building, Port Louis, 29 April 2020: In a major contribution in our fight against Covid-19, Aspen Global Incorporated, the Mauritian subsidiary of Aspen Pharmacare Holdings (a multinational pharmaceutical company), has donated approximately 30,000 vials of three… Continue reading AGI: Covid-19 support in Mauritius

Aspen responds to President Cyril Ramaphosa’s call to action on COVID-19

Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, has announced that the Group is actively focused on employees carrying out best practices in respect of the prevention and containment of COVID-19 while ensuring continued supply of medicines to patients. Stephen Saad, Aspen Group Chief Executive said, “As… Continue reading Aspen responds to President Cyril Ramaphosa’s call to action on COVID-19

Aspen increases revenue and progresses on medium-term priorities

Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, has announced unaudited interim financial results for the six months ended 31 December 2019. GROUP PERFORMANCE (CONTINUING OPERATIONS) Aspen increased revenue by 3% to R18,4 billion for the six months ended 31 December 2019. Commercial Pharma increased 2% to… Continue reading Aspen increases revenue and progresses on medium-term priorities

OPINION: Let’s pause for a moment to reflect on SA’s ARV success

By Stavros Nicolau, published in Independent Media’s Business Report JOHANNESBURG – Last week’s launch by Minister of Health Zweli Mkhize of a new ARV triple drug regimen in the Ugu district in KwaZulu-Natal and the commemoration of World Aids Day allows us as a country to reflect on how successfully we’ve managed what is arguably… Continue reading OPINION: Let’s pause for a moment to reflect on SA’s ARV success

Aspen divests of its Japanese operations for up to R6.5 billion

Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty and branded pharmaceutical company, is pleased to announced that its wholly owned subsidiary, Aspen Global Incorporated (“AGI”), has concluded an agreement to divest of Aspen’s Japanese operations and related intellectual property to Sandoz, a Novartis Division, for a cash consideration of… Continue reading Aspen divests of its Japanese operations for up to R6.5 billion

Aspen generates strong second half cash flows, reducing borrowings

Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, has announced reviewed provisional Group financial results for the year ended 30 June 2019. Stephen Saad, Aspen Group Chief Executive said, “Despite the challenging environment, we have achieved most of our short-term goals, including the completion of the disposal… Continue reading Aspen generates strong second half cash flows, reducing borrowings

Closed Period

Aspen is in a closed period from 1st January 2026 until the publication of the interim results on the JSE SENS platform on the 3rd March 2026.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.

Corporate

Our career opportunities are across the corporate spectrum, including Human Capital, Digital Technology, Legal, and Risk & Sustainability. Our employees are given the opportunity to hone their skills and develop the experience of excellence in their chosen field in the pharmaceutical industry.

View our teams below: